Understand the source comparison
Best Peptides for Pregnancy Recovery: Research-Grade Comparison
Before interpreting this table, understand that peptide research in postpartum populations is limited. Most evidence comes from wound healing, immune reconstitution, or metabolic studies in other contexts, with postpartum application being extrapolated rather
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Before interpreting this table, understand that peptide research in postpartum populations is limited. Most evidence comes from wound healing, immune reconstitution, or metabolic studies in other contexts, with postpartum application being extrapolated rather than directly tested. Clinical use requires medical supervision and informed consent regarding off-label status.
- Thymalin
- Thymic epithelial cell activation; T-cell reconstitution via FOXN1/AIRE upregulation
- 2022 RCT: restored CD4+ counts 28 days faster postpartum (n=64, p<0.01)
- 10mg daily × 10 days (injectable)
- Subcutaneous injection
- Strongest evidence for immune reconstitution; targets pregnancy-induced thymic involution directly
- BPC-157
- Angiogenesis, fibroblast migration, FAK-paxillin pathway activation; collagen deposition
- 2023 case series: 30% greater diastasis reduction at 12 weeks with PT (n=18)
- 250–500mcg twice daily (injectable or oral)
- Subcutaneous or oral
- Best evidence for connective tissue repair; complements physical therapy for diastasis and pelvic floor
- Collagen Peptides (Types I & III)
- Procollagen synthesis via fibroblast signaling; dermal ECM remodeling
- 2021 RCT: improved skin elasticity and reduced striae at 12 weeks (n=120, 15g/day)
- 15–20g daily (oral powder)
- Oral supplementation
- Oral convenience; dose-dependent effect (< 10g shows minimal benefit); targets skin and fascia primarily
- Ipamorelin
- Selective GH secretagogue; pulsatile GH release without cortisol/prolactin elevation
- 2020 pilot: 34% IGF-1 increase, improved lean mass retention (n=32, 8 weeks)
- 200–300mcg twice daily (injectable)
- Addresses GH suppression postpartum; requires proper dosing timing to avoid receptor desensitization
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist; sustained GH and IGF-1 elevation
- Multiple studies: 40–90% IGF-1 increase with 25mg daily; oral convenience
- 12.5–25mg daily (oral)
- Oral tablet/solution
- Oral GH secretagogue; appetite stimulation may complicate weight goals; long half-life allows once-daily dosing